Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-pfhbr Total loading time: 0 Render date: 2024-07-12T21:35:04.297Z Has data issue: false hasContentIssue false

8 - Apixaban

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Eliquis

Generic?

• No

Class

• Anticoagulant

Commonly Prescribed for

(FDA approved in bold)

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF)

Primary prevention of venous thromboembolic (VTE) events in adult patients who have undergone elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)

• Treatment of cerebral venous thromboembolism

How the Drug Works

• Apixaban is a selective reversible inhibitor of both free and clot-bound factor Xa, and prothrombinase activity, thereby reducing the conversion of prothrombin to thrombin and thrombus formation. Thrombin-induced platelet aggregation is also inhibited

How Long Until It Works

• Peak concentration in 3–4 hours

If It Works

• Monitor for signs of bleeding. Assess liver function periodically as clinically indicated

If It Doesn't Work

• Correct the underlying disorder. Use a higher dose or switch to different anticoagulant

Best Augmenting Combos for Partial Response or Treatment-Resistance

• None

Tests

• The degree of anticoagulation does not need to be assessed

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Reduced coagulation due to inhibited thrombin formation

Notable AEs

• Bleeding, nausea/vomiting, constipation

Life-Threatening or Dangerous AEs

• The yearly incidence of life-threatening bleed is 0.11 %, intracranial hemorrhage 0.3 %, and major GI bleed 0.83%

Weight Gain

• Unusual

Sedation

• Unusual

What to Do About AEs

• Discontinue treatment, supportive care. Active charcoal reduces absorption. Not effective: vitamin K, protamine sulfate, hemodialysis

Best Augmenting Agents to Reduce AEs

• In most cases discontinuation and changing to another medication is more practical than trying to reduce AEs with another medication

DOSING AND USE

Usual Dosage Range

• 2.5–5mg twice daily

Dosage Forms

• Tablet. 2.5 and 5mg

How to Dose For NVAF

• 2.5 mg twice daily for patients with any 2 of the following 3 factors: > 80 years old, body weight< 60 kg, serum Cr > 1.5 mg/dL

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 29 - 31
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Apixaban
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.009
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Apixaban
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.009
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Apixaban
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.009
Available formats
×